NCT06528691 2026-04-22
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
St. Jude Children's Research Hospital
Phase 2 Recruiting
Clinical Trials
14 trialsNCT05836584 2026-04-21
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06325683 2026-04-21
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Suspended
NCT02792582 2026-04-17
A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT06702033 2026-04-16
MINT-2
Washington University School of Medicine
Phase 2 Recruiting
NCT04708418 2026-04-13
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07281417 2026-04-13
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07301268 2026-04-08
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
Phase 2 Recruiting
NCT05710328 2026-04-03
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06368817 2026-03-31
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Children's Oncology Group
Phase 2 Recruiting
NCT02676349 2026-03-27
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Phase 2 Completed
NCT04503694 2026-03-27
REGINA
Jules Bordet Institute
Phase 2 Active not recruiting
NCT05826509 2026-03-27
SUGAR
Institut Claudius Regaud
Phase 2 Active not recruiting
NCT06850103 2026-03-25
SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting